MM harbors both oncogenic activating mutations of KRAS and NRAS (Fig. S5A)1, and while ALL and AML also harbor KRAS A146 mutations, these leukemias preferentially express mutant forms of NRAS44. This evidence concerns the gene KRAS and acute myeloid leukemia.